Monica L Kasting1,2, Shannon M Christy3,4,5,6, Richard R Reich7, Julie A Rathwell5,8, Richard G Roetzheim3,9, Susan T Vadaparampil3,4,5, Anna R Giuliano5,8. 1. 311308 Department of Public Health, Purdue University, West Lafayette, IN, USA. 2. Cancer Prevention and Control Program, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, USA. 3. 25301 Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA. 4. 33697 Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA. 5. Center for Immunization and Infection Research in Cancer, Moffitt Cancer Center, Tampa, FL, USA. 6. Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA. 7. Biostatistics and Bioinformatics Shared Resource, Moffitt Cancer Center, Tampa, FL, USA. 8. Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA. 9. Department of Family Medicine, University of South Florida, Tampa, FL, USA.
Abstract
OBJECTIVES: In 2012, onetime hepatitis C virus (HCV) screening was recommended for all baby boomers (people born during 1945-1965) in the United States, but only 4.0%-12.9% of baby boomers have ever had a screening ordered by a health care provider. This study examined the HCV screening prevalence among adult patients in a large academic health care system and assessed factors associated with the completion of screening when ordered for baby boomers. METHODS: We defined HCV screening completion as the completion of an HCV antibody test when it was ordered. We used electronic health records to examine HCV screening completion rates among adults (N = 106 630) from August 1, 2015, through July 31, 2020, by birth cohort. Among baby boomers whose health care provider ordered HCV screening, we examined frequency and percentages of HCV screening completion by sociodemographic and clinical characteristics. We conducted univariate and multivariable logistic regression analyses to assess factors associated with HCV screening completion among baby boomers. RESULTS: During the study period, 73.0% of baby boomers completed HCV screening when it was ordered. HCV completion did not differ by sex or race and ethnicity among baby boomers. Baby boomers with Medicare supplemental health insurance compared with commercial health insurance (adjusted odds ratio [aOR] = 1.87) and those seeing only advanced practice professionals compared with specialty care physicians (aOR = 2.24) were more likely to complete HCV screening when it was ordered. CONCLUSIONS: Noncompletion of HCV screening is one of many barriers along the HCV treatment continuum. Our findings suggest a need for interventions targeting systems, health care providers, and patients to increase HCV screening rates in the United States.
OBJECTIVES: In 2012, onetime hepatitis C virus (HCV) screening was recommended for all baby boomers (people born during 1945-1965) in the United States, but only 4.0%-12.9% of baby boomers have ever had a screening ordered by a health care provider. This study examined the HCV screening prevalence among adult patients in a large academic health care system and assessed factors associated with the completion of screening when ordered for baby boomers. METHODS: We defined HCV screening completion as the completion of an HCV antibody test when it was ordered. We used electronic health records to examine HCV screening completion rates among adults (N = 106 630) from August 1, 2015, through July 31, 2020, by birth cohort. Among baby boomers whose health care provider ordered HCV screening, we examined frequency and percentages of HCV screening completion by sociodemographic and clinical characteristics. We conducted univariate and multivariable logistic regression analyses to assess factors associated with HCV screening completion among baby boomers. RESULTS: During the study period, 73.0% of baby boomers completed HCV screening when it was ordered. HCV completion did not differ by sex or race and ethnicity among baby boomers. Baby boomers with Medicare supplemental health insurance compared with commercial health insurance (adjusted odds ratio [aOR] = 1.87) and those seeing only advanced practice professionals compared with specialty care physicians (aOR = 2.24) were more likely to complete HCV screening when it was ordered. CONCLUSIONS: Noncompletion of HCV screening is one of many barriers along the HCV treatment continuum. Our findings suggest a need for interventions targeting systems, health care providers, and patients to increase HCV screening rates in the United States.
Entities:
Keywords:
health care utilization; hepatitis C virus screening; hepatocellular carcinoma; viral hepatitis
Authors: Monica A Konerman; Mary Thomson; Kristen Gray; Meghan Moore; Hetal Choxi; Elizabeth Seif; Anna S F Lok Journal: Hepatology Date: 2017-09-14 Impact factor: 17.425
Authors: Alexander G Geboy; Sandeep Mahajan; Allison P Daly; Candice F Sewell; Ike C Fleming; Hyun A Cha; Idene E Perez; Carmella A Cole; Adebisi A Ayodele; Dawn A Fishbein Journal: Public Health Rep Date: 2016 May-Jun Impact factor: 2.792
Authors: Melissa R Partin; Amy A Gravely; James F Burgess; David A Haggstrom; Sarah E Lillie; David B Nelson; Sean M Nugent; Aasma Shaukat; Shahnaz Sultan; Louise C Walter; Diana J Burgess Journal: Cancer Date: 2017-05-11 Impact factor: 6.860
Authors: Monica L Kasting; Anna R Giuliano; Richard R Reich; Richard G Roetzheim; Linh M Duong; Emmanuel Thomas; David R Nelson; Elizabeth Shenkman; Susan T Vadaparampil Journal: Cancer Epidemiol Date: 2019-04-03 Impact factor: 2.984
Authors: James W Galbraith; Ricardo A Franco; John P Donnelly; Joel B Rodgers; Jordan M Morgan; Andres F Viles; Edgar T Overton; Michael S Saag; Henry E Wang Journal: Hepatology Date: 2015-01-28 Impact factor: 17.425
Authors: Alex D Federman; Natalie Kil; Joseph Kannry; Evie Andreopolous; Wilma Toribio; Joanne Lyons; Mark Singer; Anthony Yartel; Bryce D Smith; David B Rein; Katherine Krauskopf Journal: Med Care Date: 2017-06 Impact factor: 2.983
Authors: Monica L Kasting; Anna R Giuliano; Richard R Reich; Richard G Roetzheim; David R Nelson; Elizabeth Shenkman; Susan T Vadaparampil Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-03-27 Impact factor: 4.254